Skip to main content
SpringerLink
Log in

Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force

  • CTAD Task Force Paper
  • Published:
The Journal of Prevention of Alzheimer's Disease Aims and scope Submit manuscript

Abstract

Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Hendrix JA, Bateman RJ, Brashear HR, et al. Challenges, solutions, and recommendations for Alzheimer’s disease combination therapy. Alzheimers Dement 2016;12:623–630.

    Article  PubMed  Google Scholar 

  2. Perry D, Sperling R, Katz R, et al. Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Rev Neurother 2015;15:327–333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Stephenson D, Perry D, Bens C, et al. Charting a path toward combination therapy for Alzheimer’s disease. Expert Rev Neurother 2015;15:107–113.

    Article  CAS  PubMed  Google Scholar 

  4. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 2018;14:367–429.

    Article  Google Scholar 

  5. Alzheimer’s Disease International. World Alzheimer’s Report 2018. The state of the art of dementia research: New frontiers. London 2018.

    Google Scholar 

  6. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement (N Y) 2017;3:367–384.

    Google Scholar 

  7. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network. The New England journal of medicine 2012;367:795–804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Schindler RJ. Study design considerations: conducting global clinical trials in early Alzheimer’s disease. J Nutr Health Aging 2010;14:312–314.

    Article  CAS  PubMed  Google Scholar 

  9. Sperling R, Cummings J, Donohue M, Aisen P. Global Alzheimer’s Platform Trial Ready Cohorts for the Prevention of Alzheimer’s Dementia. J Prev Alzheimers Dis 2016;3:185–187.

    CAS  PubMed  Google Scholar 

  10. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 2016;8:595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 2012;488:96–99.

    Article  CAS  PubMed  Google Scholar 

  12. Serrano-Pozo A, Betensky RA, Frosch MP, Hyman BT. Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am J Pathol 2016;186:375–384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 2012;15:349–357.

    Article  CAS  PubMed  Google Scholar 

  14. O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011;34:185–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sims JR, Selzler KJ, Downing AM, et al. Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814). J Prev Alzheimers Dis 2017;4:247–254.

    CAS  PubMed  Google Scholar 

  16. Budd Haeberlein S, O’Gorman J, Chiao P, et al. Clinical Development of Aducanumab, an Anti-Abeta Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer’s Disease. J Prev Alzheimers Dis 2017;4:255–263.

    CAS  PubMed  Google Scholar 

  17. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535–562.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement (N Y) 2018;4:195–214.

    Google Scholar 

  19. Hara Y, McKeehan N, Fillit HM. Translating the biology of aging into novel therapeutics for Alzheimer disease. Neurology 2019;92:84–93.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Jack CR, Jr., Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765–775.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tomaszewski S, Gauthier S, Wimo A, Rosa-Neto P. Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer’s Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer. J Prev Alzheimers Dis 2016;3:164–172.

    CAS  PubMed  Google Scholar 

  22. Hendrix S, Ellison N, Stanworth S, Otcheretko V, Tariot PN. Post Hoc Evidence for an Additive Effect of Memantine and Donepezil: Consistent Findings from DOMINO-AD Study and Memantine Clinical Trial Program. J Prev Alzheimers Dis 2015;2:165–171.

    CAS  PubMed  Google Scholar 

  23. Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: Adaptive design and disease progression model. Alzheimers Dement 2017;13:8–19.

    Article  PubMed  Google Scholar 

  24. Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials 2016;13:358–366.

    Article  PubMed  Google Scholar 

  25. Food and Drug Administration. Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination.. Accessed online 4/13/14 at https://doi.org/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf, 2013.

    Google Scholar 

  26. Irizarry MC, Fleisher AS, Hake AM, et al. TRAILBLAZER-ALZ (NCT03367403): A Phase 2 disease-modification combination therapy trial targeting multiple mechanisms of action along the amyloid pathway. Alzheimer Dement 2018;14:P1622–P1623.

    Article  Google Scholar 

  27. DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer’s disease mice. Neuron 2012;76:908–920.

    Article  CAS  PubMed  Google Scholar 

  28. DeMattos R, May P, Racke M, et al. Combination therapy with a plaque-specific Abeta antibody and BACE inhibitor results in dramatic plaque lowering in aged PDAPP transgenic mice. Alzheimer Dement 2014;10:P149.

    Article  Google Scholar 

  29. Wessels AM, Siemers ER, Yu P, et al. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alzheimers Dis 2015;2:227–241.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Panza F, Lozupone M, Solfrizzi V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Rev Neurother 2018;18:847–857.

    Article  CAS  PubMed  Google Scholar 

  31. Vellas B, Bain LJ, Touchon J, et al. Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018. J Prev Alzheimers Dis. 2019; in press

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. McGill Center for Studies in Aging, Verdun, QC, Canada

    Serge Gauthier

  2. EIP Pharma Inc., Cambridge, MA, USA

    J. Alam

  3. The Alzheimer’s Drug Discovery Foundation, New York, NY, USA

    H. Fillit

  4. University of Tokyo, Tokyo, Japan

    T. Iwatsubo

  5. Eli Lilly and Company, Indianapolis, IN, USA

    H. Liu-Seifert & J. R. Sims

  6. L Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

    M. Sabbagh

  7. The Warren Alpert Medical School of Brown University, Providence, RI, USA

    S. Salloway

  8. CHDI Foundation, Princeton, NJ, USA

    C. Sampaio

  9. Lundbeck, Valby, 2500, Copenhagen, Denmark

    B. Sperling

  10. Brigham and Women’s Hospital, Boston, MA, USA

    R. Sperling

  11. Duke University, Durham, NC, USA

    K. A. Welsh-Bohmer

  12. University Hospital of Montpellier, 34025, Montpellier Cedex 5, France

    J. Touchon

  13. INSERM 1061, Montpellier, France

    J. Touchon

  14. Gerontopole, INSERM U1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

    B. Vellas

  15. Alzheimer’s Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, CA, USA

    P. Aisen

Authors
  1. Serge Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Fillit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Iwatsubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Liu-Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Sabbagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Salloway
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Sampaio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. R. Sims
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B. Sperling
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Sperling
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K. A. Welsh-Bohmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. Touchon
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. B. Vellas
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P. Aisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

EU/US/CTAD Task Force

Corresponding author

Correspondence to Serge Gauthier.

Additional information

EU/US/CTAD TASK FORCE: Bjorn Aaris Gronning (Valby); Paul Aisen (San Diego); John Alam (Cambridge); Sandrine Andrieu (Toulouse), Randall Bateman (St. Louis); Monika Baudler (Basel); Joanne Bell (Wilmington); Kaj Blennow (Mölndal); Claudine Brisard (Blue Bell); Samantha Budd-Haeberlein (USA); Szofia Bullain (Basel); Marc Cantillon (Princeton); Maria Carrillo (Chicago); Gemma Clark (Princeton); Jeffrey Cummings (Las Vegas); Daniel Di Giusto (Basel); Rachelle Doody (Basel); Sanjay Dubé (Aliso Viejo); Michael Egan (North Wales); Howard Fillit (New York); Adam Fleisher (Philadelphia); Mark Forman (North Wales); Cecilia Gabriel-Gracia (Suresnes); Serge Gauthier (Verdun); Jeffrey Harris (South San Francisco); Suzanne Hendrix (Salt Lake City); Dave Henley (Titusville); David Hewitt (Blue Bell); Mads Hvenekilde (Basel); Takeshi Iwatsubo (Tokyo); Keith Johnson (Boston); Michael Keeley (South San Francisco); Gene Kinney (South San Francisco); Ricky Kurzman (Woodcliffe Lake); Valérie Legrand (Nanterre); Stefan Lind (Valby); Hong Liu-Seifert (Indianapolis); Simon Lovestone (Oxford); Johan Luthman (Woodcliffe); Annette Merdes (Munich); David Michelson (Cambridge); Mark Mintun (Philadelphia); José Luis Molinuevo (Barcelona); Susanne Ostrowitzki (South San Francisco); Anton Porsteinsson (Rochester); Martin Rabe (Woodcliffe Lake); Rema Raman (San Diego); Elena Ratti (Cambridge); Larisa Reyderman (Woodcliffe Lake); Gary Romano (Titusville); Ivana Rubino (Cambridge); Marwan Noel Sabbagh (Las Vegas); Stephen Salloway (Providence); Cristina Sampaio (Princeton); Rachel Schindler (USA); Peter Schüler (Langen); Dennis Selkoe (Boston); Eric Siemers (New York); John Sims (Indianapolis); Heather Snyder (Chicago); Georgina Spence (Galashiels); Bjorn Sperling (Valby); Reisa Sperling (Boston); Andrew Stephens (Berlin); Joyce Suhy (Newark); Gilles Tamagnan (New Haven); Edmond Teng (South San Francisco); Gary Tong (Valby); Jan Torleif Pedersen (Valby); Jacques Touchon (Montpellier); Bruno Vellas (Toulouse); Vissia Viglietta (Cambridge); Christian Von Hehn (Cambridge); Philipp Von Rosenstiel (Cambridge); Michael Weiner (San Francisco); Kathleen Welsh-Bohmer (Durham); Iris Wiesel (Basel); Haichen Yang (North Wales); Wagner Zago (South San Francisco); Beyhan Zaim (Woodcliffe Lake); Henrik Zetterberg (Mölndal)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gauthier, S., Alam, J., Fillit, H. et al. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis 6, 164–168 (2019). https://doi.org/10.14283/jpad.2019.12

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.14283/jpad.2019.12

Key words

Search

Navigation